The LIMK1 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human Raji B lymphocyte line, offering a loss-of-function model for LIMK1. This genetically heterogeneous pool, generated by CRISPR/Cas9-mediated gene disruption, is suited for experiments not requiring clonal uniformity. The Raji host line, an EBV-positive Burkitt??s lymphoma model, is well-established for B cell receptor (BCR) signaling, antigen presentation, and adaptive immunity studies.
Raji cells, established from a Burkitt??s lymphoma patient, retain features of mature B lymphocytes and harbor Epstein-Barr virus. Widely used to dissect BCR-mediated signal transduction and lymphoma pathogenesis, this line provides a relevant context for examining oncogenic signaling and immune synapse formation. The knockout model leverages this background to study LIMK1-dependent actin dynamics in normal B cell biology and malignant transformation.
LIMK1 is a serine/threonine kinase that regulates actin dynamics by phosphorylating cofilin at Ser3, thereby inhibiting actin severing and promoting filament stabilization. Activated downstream of Rho GTPases (Rac1, Cdc42, RhoA) by PAK1, PAK2, ROCK1, and ROCK2, it drives lamellipodia formation, cell motility, and adhesion. BCR signaling and the CXCL12/CXCR4 axis act as upstream regulators, while downstream targets include SRF/MRTF transcriptional activity. Key interacting partners comprise 14-3-3, Nck, and the phosphatase SSH1. Thus, LIMK1 integrates multiple signals into coordinated actin remodeling.
In B lymphocytes, LIMK1 controls immune synapse assembly, BCR clustering, and chemokine-driven migration. The Raji knockout pool enables dissection of these processes, including actin-rich structure formation at the immunological synapse and adhesion molecule regulation. Aberrant LIMK1 activity is linked to lymphoma invasiveness, making this model valuable for studying malignant B cell migration and metastasis. The polyclonal nature allows assessment of population-level phenotypes, with single-cell analysis options for editing variability.
Key assays include western blot for LIMK1 and phospho-cofilin, phalloidin-based F-actin imaging, and Transwell migration/invasion assays. BCR stimulation coupled with phospho-signaling analysis reveals proximal signaling defects, while flow cytometry quantifies adhesion molecules. Co-immunoprecipitation confirms interactions with PAK1 or cofilin, and RNA-seq can profile transcriptional changes. The model is also amenable to high-throughput LIMK1 inhibitor screening. For further inquiries, please contact Ascent Research.
